PROCEPT BIOROBOTICS CORPORATION PROCEPT BioRobotics Corporation Stock
Equities
PRCT
US74276L1052
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 62.65 USD | -0.56% |
|
-2.58% | +49.49% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 214M | Sales 2025 * | 300M | Capitalization | 3.24B |
|---|---|---|---|---|---|
| Net income 2024 * | -99M | Net income 2025 * | -76M | EV / Sales 2024 * | 15.2 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 10.8 x |
| P/E ratio 2024 * |
-32.6
x | P/E ratio 2025 * |
-43.3
x | Employees | 626 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.95% |
More Fundamentals
* Assessed data
More news
Latest transcript on PROCEPT BioRobotics Corporation
More recommendations
More press releases
More news
| 1 day | +0.29% | ||
| 1 week | -1.54% | ||
| Current month | +19.52% | ||
| 1 month | +21.23% | ||
| 3 months | +25.34% | ||
| 6 months | +104.26% | ||
| Current year | +51.09% |
1 week
60.14
65.00
1 month
48.5065.00
Current year
39.4865.00
1 year
24.8365.00
3 years
15.3865.00
5 years
15.3865.00
10 years
15.3865.00
| Managers | Title | Age | Since |
|---|---|---|---|
Reza Zadno
CEO | Chief Executive Officer | 69 | 20-02-05 |
Kevin Waters
DFI | Director of Finance/CFO | 46 | - |
Barry Templin
CTO | Chief Tech/Sci/R&D Officer | - | 16-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Frederic Moll
CHM | Chairman | 72 | 11-07-31 |
Taylor Harris
BRD | Director/Board Member | 48 | 20-12-16 |
Reza Zadno
CEO | Chief Executive Officer | 69 | 20-02-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.60% | 0 M€ | -4.02% | ||
| 0.05% | 0 M€ | +3.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 62.65 | -0.56% | 411 370 |
| 24-05-09 | 63 | +4.37% | 442,451 |
| 24-05-08 | 60.36 | -3.87% | 602,745 |
| 24-05-07 | 62.79 | +2.21% | 679,200 |
| 24-05-06 | 61.43 | -4.48% | 1,077,113 |
Delayed Quote Nasdaq, May 10, 2024 at 11:30 am EDT
More quotes
PROCEPT BioRobotics Corporation is a surgical robotics company, which is focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures and sells the AquaBeam Robotic System, which is an image-guided surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). The AquaBeam Robotic System employs a single-use disposable handpiece to deliver the Companyâs proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The Company designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, (LUTS), due to BPH that are independent of prostate size and shape or surgeon experience.
Calendar
2024-05-15
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
63
USD
Average target price
70.83
USD
Spread / Average Target
+12.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +51.09% | 3.24B | |
| -4.68% | 182B | |
| +0.14% | 110B | |
| -3.94% | 67.92B | |
| +3.09% | 50.96B | |
| +9.59% | 44.7B | |
| +2.70% | 40.66B | |
| +20.72% | 27.6B | |
| +4.19% | 26.63B | |
| -0.46% | 24.98B |
- Stock Market
- Equities
- PRCT Stock